Dianthus Therapeutics, Inc.(DNTH)Earnings, Financials & Key RatiosDianthus Therapeutics, Inc. (DNTH) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's operating cash flow is consistently negative, with a 2026Q1 net loss of $40.8 million and a high reliance on stock-based compensation of $10.6 million to manage expenses.
Dianthus Therapeutics, Inc. (DNTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Dianthus Therapeutics, Inc. (DNTH) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.85vs $1.17+27.4% | $463,000vs $403,615+14.7% |
| Q2 2026 | Mar 9, 2026 | $1.43vs $0.98-45.9% | $284,000vs $552,231-48.6% |
| Q4 2025 | Nov 5, 2025 | $0.97vs $0.86-12.8% | $396,000vs $398,090-0.5% |
| Q3 2025 | Aug 7, 2025 | $0.88vs $0.86-2.3% | $193,000vs $864,670-77.7% |
Recent stock market news and headlines for Dianthus Therapeutics, Inc. (DNTH)
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Key metrics vs top competitors for Dianthus Therapeutics, Inc. (DNTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $93.34 | $3.9B | -22.22 | -67.35% | -7973.33% | -38.38% | — | |
| $2.19 | $118.76M | -1.15 | — | — | -124.06% | — | |
| $4.58 | $5.78M | -0.09 | -81.82% | -2530.85% | — | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $41.03 | $5.25B | 227.94 | 28.46% | 12.95% | 39.71% | — |
Dianthus Therapeutics, Inc. (DNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Dianthus Therapeutics, Inc. (DNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Mar 26, 2026·SEC
Mar 12, 2026·SEC
Get notified when DNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dianthus Therapeutics, Inc. (DNTH) stock FAQ — growth, dividends, profitability & financials explained
Dianthus Therapeutics, Inc. (DNTH) reported $1.3M in revenue for fiscal year 2025.
Dianthus Therapeutics, Inc. (DNTH) saw revenue decline by 67.3% over the past year.
Dianthus Therapeutics, Inc. (DNTH) reported a net loss of $11.3M for fiscal year 2025.
Dianthus Therapeutics, Inc. (DNTH) has a return on equity (ROE) of -38.4%. Negative ROE indicates the company is unprofitable.
Dianthus Therapeutics, Inc. (DNTH) had negative free cash flow of $130.5M in fiscal year 2025, likely due to heavy capital investments.
